Silvan Tuerkcan
Stock Analyst at Citizens
(3.59)
# 840
Out of 5,055 analysts
180
Total ratings
44.89%
Success rate
7.19%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $8.53 | +146.19% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $8.70 | +141.38% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.13 | +93.70% | 14 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $6 → $8 | $4.86 | +64.61% | 4 | Nov 4, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $13.16 | +67.17% | 14 | Nov 4, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $20 → $15 | $22.56 | -33.51% | 13 | Oct 23, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.68 | +257.14% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $21.77 | +56.18% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $32.14 | +40.01% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $41.65 | +20.05% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $86 | $52.53 | +63.72% | 16 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $4.24 | +253.77% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.37 | +78.04% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.69 | +91.90% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $10.01 | +1,098.80% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.24 | +658.93% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.42 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.16 | +244.83% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $6.29 | +233.86% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.50 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.90 | +53.85% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $160.54 | +74.41% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.68 | +85.95% | 1 | Jan 26, 2023 |
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $8.53
Upside: +146.19%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $8.70
Upside: +141.38%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.13
Upside: +93.70%
Nuvation Bio
Nov 4, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.86
Upside: +64.61%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $13.16
Upside: +67.17%
Terns Pharmaceuticals
Oct 23, 2025
Maintains: Market Outperform
Price Target: $20 → $15
Current: $22.56
Upside: -33.51%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.68
Upside: +257.14%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $21.77
Upside: +56.18%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $32.14
Upside: +40.01%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $41.65
Upside: +20.05%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $52.53
Upside: +63.72%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.24
Upside: +253.77%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.37
Upside: +78.04%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.69
Upside: +91.90%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $10.01
Upside: +1,098.80%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.24
Upside: +658.93%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.42
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.16
Upside: +244.83%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $6.29
Upside: +233.86%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.50
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.90
Upside: +53.85%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $160.54
Upside: +74.41%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.68
Upside: +85.95%